Overvægt kliniske forsøg i Oklahoma
18 studier for Overvægt søger deltagere på steder i Oklahoma.
Byer i Oklahoma
Officiel studietekst (engelsk)
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
- Children's Physicians OU, Oklahoma City
RekruttererFase 3
Alder 8 til 18 · Alle køn · Opdateret 30. sep. 2026 · NCT07253285Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss
- Lynn Health Science Institute, Oklahoma City
RekruttererFase 2
Alder 18 til 75 · Alle køn · Opdateret 28. sep. 2026 · NCT07837973AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight
- Lynn Institute of Norman, Norman
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 28. sep. 2026 · NCT07720271A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
- Central States Research, Tulsa
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 28. sep. 2026 · NCT07794579A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
- University of Oklahoma Health Sciences Center, Oklahoma City
RekruttererFase 3
Alder 6 til 17 · Alle køn · Opdateret 24. sep. 2026 · NCT06672549Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
- Central States Research, Tulsa
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 22. sep. 2026 · NCT07353931A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
- AURORA-2 Clinical Site, Oklahoma City
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 16. sep. 2026 · NCT07743450A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
- Lynn Institute of Norman, Norman
- Lynn Health Science Institute, Oklahoma City
- Essential Medical Research, Tulsa
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 14. sep. 2026 · NCT07351058A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
- Alliance for Multispecialty Research, LLC, Norman
RekruttererFase 2
Alder 18 til 75 · Alle køn · Opdateret 14. sep. 2026 · NCT06897475A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
- Delricht Research of Tulsa Clinical Trials, Tulsa
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 14. sep. 2026 · NCT07351045A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
- ACCOMPLISH-2 Research Site, Moore
- ACCOMPLISH-2 Research Site, Tulsa
- ACCOMPLISH-2 Research Site, Yukon
RekruttererFase 3Frivillige med god helbredstilstand velkomne
Alder 18 til 79 · Alle køn · Opdateret 11. sep. 2026 · NCT07654374Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
- Kailera Clinical Site, Chickasha
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 3. sep. 2026 · NCT07284901Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
- Alliance for Multispecialty Research - Norman, Norman
RekruttererFase 3
Alder 18 til 99 · Alle køn · Opdateret 3. sep. 2026 · NCT07684235Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes
- Kailera Clinical Site, Chickasha
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 3. sep. 2026 · NCT07284875Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
- Epic Medical Research - Oklahoma, Chickasha
- Lynn Health Science Institute, Oklahoma City
RekruttererFase 3
Alder 18 til 99 · Alle køn · Opdateret 27. aug. 2026 · NCT07575399A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
- Research Site, Tulsa
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 25. aug. 2026 · NCT07784725Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
- ACCOMPLISH-1 Research Site, Moore
RekruttererFase 3
Alder 18 til 79 · Alle køn · Opdateret 10. aug. 2026 · NCT07654361Intensive Glycemic Targets in Overweight and Obese Women With Gestational Diabetes
- University of Oklahoma, Norman
Rekrutterer
Alder 18 til 45 · Kvinder · Opdateret 24. jun. 2026 · NCT05124808Fra ClinicalTrials.gov, data hentet 3. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.